Drug intelligence / Profile preview

DISC-201

Development stage: Preclinical
Lead developer: Dualitas Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

DISC-201 is a preclinical-stage bispecific antibody being developed by Dual Therapeutics (also known as Dualitas Therapeutics) for the treatment of allergic diseases. The drug was identified using the company's proprietary DualScreen™ Bispecific Discovery Engine, a platform designed to discover and optimize bispecific antibodies by screening for functional activity. As of early 2024, the specific molecular targets and the exact mechanism of action for DISC-201 remain undisclosed, though it is positioned within the company's discovery pipeline alongside other early-stage programs such as DTX-101 and DISC-202. The program is currently in the discovery/preclinical phase of development.

Beyond the preview

Go deeper on DISC-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DISC-201.

Explore the full profile